NCT Number: NCT00059800
Boron Neutron Capture Therapy in Treating Patients With Melanoma
RATIONALE: Boron neutron capture therapy may selectively kill tumor cells without harming normal tissue.
PURPOSE: Phase II trial to study the effectiveness of boron neutron capture therapy in treating patients who have melanoma.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
About this study
OBJECTIVES:
- Determine the clinical response, by serial objective measurements, in patients with melanoma treated with boron neutron capture therapy.
- Determine the time course, uniformity, and severity of acute dermal reactions in patients treated with this regimen.
- Determine the late dermal reactions in patients who are followed for at least 6 months after treatment with this regimen.
- Determine the pharmacokinetics of this regimen in these patients.
OUTLINE: Patients are stratified according to tumor size (no greater than 15 cc vs greater than 15 cc).
Patients undergo boron neutron capture therapy.
Patients are followed for 3 years.
PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study within 3 years.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
DISEASE CHARACTERISTICS:
- Histologically confirmed melanoma
- Evaluable disease
- Lesion(s) to be irradiated must be located in 1 of the following areas:
- On an extremity
- On the head or neck (including the scalp)
- In the subdermal lymphatics (excluding the proximal axilla)
- Area to be irradiated must not exceed a maximum dimension of 10 cm
- Maximum tumor depth from the surface of the skin cannot exceed 6 cm
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-1
Life expectancy
- More than 6 months
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Creatinine normal
Cardiovascular
- No history of severe cardiac disease
- No uncontrolled arrhythmias or conduction defects
- No unstable or newly diagnosed angina pectoris
- No recent coronary artery disease
- No congestive heart failure
Other
- Not pregnant
- Negative pregnancy test
- No history of phenylketonuria
- Must have sufficient mental competence
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- Not specified
Endocrine therapy
- Not specified
Radiotherapy
- No prior radiotherapy to study sites
Surgery
- Not specified
Treatment and study plan
Primary outcomes
-
Clinical response
-
Time course, uniformity, and severity of acute dermal reactions
-
Late dermal reaction after at least six months
-
Pharmacokinetics
Sponsors and collaborators
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Registry information
Official study title
A Phase II Trial For Neutron Capture Therapy In Melanoma
Important dates
- Study start
- 2002
- Study completion
- 2004
- First posted
- May 7, 2003
- Registry last updated
- Jun 26, 2013
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery
NCT03405155
Melanoma, Melanoma (Skin)
New Brunswick, New Jersey, United States
View Trial DetailsDermoscopy Augmented Histology Trial, Consensus Agreement Diagnosis Made by Dermatopathology Experts
NCT05712551
Melanoma, Melanoma (Skin)
Herlev, Denmark
View Trial DetailsNew Tumor Models in Three Dimensions and in a Human Skin Environment for Personalized Melanoma Therapy
NCT03136783
Melanoma, Melanoma (Skin)
Amiens, Picardie, France
View Trial DetailsCryotherapy With in Situ Immunotherapy in Melanoma Metastasis
NCT03949153
Melanoma, Melanoma (Skin)
Strasbourg, France
View Trial Details